A Multicentre, Open-Label, Extension Study to Investigate the Safety and Efficacy of AD 923 (Fentanyl Sublingual) for the Treatment of Breakthrough Cancer Pain in Subjects with Malignancies [Ensayo multicentrico, abierto y de extension para evaluar la seguridad y la eficacia de AD 923 (Fentanilo sublingual) en el tratamiento del dolor irruptivo en sujetos con procesos malignos]

Trial Profile

A Multicentre, Open-Label, Extension Study to Investigate the Safety and Efficacy of AD 923 (Fentanyl Sublingual) for the Treatment of Breakthrough Cancer Pain in Subjects with Malignancies [Ensayo multicentrico, abierto y de extension para evaluar la seguridad y la eficacia de AD 923 (Fentanilo sublingual) en el tratamiento del dolor irruptivo en sujetos con procesos malignos]

Discontinued
Phase of Trial: Phase III

Latest Information Update: 07 Sep 2013

At a glance

  • Drugs Fentanyl (Primary)
  • Indications Cancer pain
  • Focus Adverse reactions
  • Most Recent Events

    • 17 Mar 2012 Planned end date changed from 21 Apr 2009 to 1 Mar 2009 as reported by European Clinical Trials Database.
    • 18 Aug 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top